Cargando…

Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

Detalles Bibliográficos
Autores principales:	Cohen, Alexander T., Ay, Cihan, Hainaut, Philippe, Décousus, Hervé, Hoffmann, Ulrich, Gaine, Sean, Coppens, Michiel, da Silva, Pedro Marques, Jimenez, David, Amann-Vesti, Beatrice, Brüggenjürgen, Bernd, Levy, Pierre, Bastida, Julio Lopez, Vicaut, Eric, Laeis, Petra, Fronk, Eva-Maria, Zierhut, Wolfgang, Malzer, Thomas, Bramlage, Peter, Agnelli, Giancarlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977454/ https://www.ncbi.nlm.nih.gov/pubmed/29855634 http://dx.doi.org/10.1186/s12959-018-0173-5

Ejemplares similares

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
por: Cohen, Alexander T., et al.
Publicado: (2018)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
por: de Groot, Joris R, et al.
Publicado: (2020)

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study
por: de Vries, T. A. C., et al.
Publicado: (2021)

Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
por: Boriani, Giuseppe, et al.
Publicado: (2021)

Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry
por: Patti, Giuseppe, et al.
Publicado: (2022)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

The management of acute venous thromboembolism in clinical practice: Results from the European PREFER in VTE Registry
por: Cohen, Alexander T., et al.
Publicado: (2017)

Safety and Effectiveness of Edoxaban in Japanese Venous Thromboembolism Patients　― Final Analysis of One-Year Follow-up Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan) ―
por: Nakamura, Mashio, et al.
Publicado: (2020)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

ANTIHEPATOTOXIC ACTICITY OF COCCINIA INDICA
por: Gopalakrishnan, V., et al.
Publicado: (2001)

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design
por: Colonna, Paolo, et al.
Publicado: (2018)

Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT‐AF/VTE study
por: Colonna, Paolo, et al.
Publicado: (2020)

Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database
por: Chen, Cathy, et al.
Publicado: (2023)

Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program
por: Chao, Tze-Fan, et al.
Publicado: (2023)

The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry
por: Agnelli, Giancarlo, et al.
Publicado: (2015)

Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry
por: Schnabel, Renate B, et al.
Publicado: (2023)

Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study
por: Medina, Andria, et al.
Publicado: (2017)

Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE
por: Santamaria, Amparo, et al.
Publicado: (2023)

Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)
por: Guo, X Y, et al.
Publicado: (2023)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis( )
por: Diemberger, Igor, et al.
Publicado: (2022)

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
por: Yamashita, Takeshi, et al.
Publicado: (2018)

Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
por: Yamashita, Takeshi, et al.
Publicado: (2020)

Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
por: Nagashima, Koichi, et al.
Publicado: (2020)

Edoxaban treatment in atrial fibrillation in routine clinical care: One‐year outcomes of the prospective observational ETNA‐AF study in South Korean patients
por: Choi, Eue‐Keun, et al.
Publicado: (2023)

Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial
por: Vranckx, Pascal, et al.
Publicado: (2020)

Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program
por: De Caterina, Raffaele, et al.
Publicado: (2021)

Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two‐year postmarketing surveillance study (ETNA‐AF‐Japan)
por: Yamashita, Takeshi, et al.
Publicado: (2021)

Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry
por: Lopez-Bastida, J., et al.
Publicado: (2021)

Vascular plant species diversity of Mt. Etna (Sicily): endemicity, insularity and spatial patterns along the altitudinal gradient of the highest active volcano in Europe
por: Sciandrello, Saverio, et al.
Publicado: (2020)

Convergent validity of ActiGraph and Actical accelerometers for estimating physical activity in adults
por: Duncan, Scott, et al.
Publicado: (2018)

Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai‐VTE study
por: Scheres, LJJ, et al.
Publicado: (2018)

Basic and clinical immunology – 3021. Inhibitory action of levocetirzine hydrochloride on eosinophil actication in vitro
por: Furuta, Atsuko, et al.
Publicado: (2013)

Actical Accelerometry Cut-Points for Quantifying Levels of Exertion: Comparing Normal and Overweight Adults
por: GIFFUNI, JAMIE, et al.
Publicado: (2012)

Publishing clinical prActice GuidelinEs (PAGE): Recommendations from editors and reviewers()
por: Yang, Nan, et al.
Publicado: (2022)

Rationale and design of a prospective, multicenter, cohort study on the evaluation of postoperative Venous ThromboEmbolism incidence in patients with ColoRectal Cancer (CRC-VTE trial)
por: Wei, Qi, et al.
Publicado: (2022)

Comparison of VTE risk scores in guidelines for VTE diagnosis in nonsurgical hospitalized patients with suspected VTE
por: Xiong, Wei, et al.
Publicado: (2023)

Translation equations to compare ActiGraph GT3X and Actical accelerometers activity counts
por: Straker, Leon, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4lv983v653qh8406s9kicepc40